Navigation Links
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Date:4/16/2008

retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through its website at http://www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to http://www.Sedar.com. For SEDAR filings prior to July 10, 2007 you will find these under the company profile for Global Summit Real Estate Inc. (Old Lorus).


'/>"/>
SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... (PRWEB) September 22, 2014 Invisible ... diagnostics for the food and beverage industries, announced ... be distributed under a non-exclusive agreement by Enartis, ... services. , Enartis, an Esseco Group company headquartered ... winemakers in California and other global markets for ...
(Date:9/22/2014)... Corporation (Nasdaq: NEOG ) announced today that ... fiscal year, which ended Aug. 31, was $8,883,000 — ... in the first quarter of last year. Adjusted for ... per share in the current quarter were $0.24, compared ... revenues increased 15% to $67,599,000, from the previous year,s ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/22/2014)... Norway (PRWEB) September 22, 2014 ... new parcel and pallet measuring device CNS110 ... eliminates manual data entry, offering greater ease and ... savings that result can significantly enhance productivity—an important ... industries where processing volume equals profits. , ...
Breaking Biology Technology:Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2ScanTape™ Handheld Dimensioner Increases Processing Volume 2
... 12 Epeius Biotechnologies Corporation today announced more stunning ... world,s first and, so far only, tumor-targeted genetic medicine ... therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has ... much-touted biologics have failed to do: that is, to ...
... ImaginAb, Inc. and BZL Biologics, LLC have concluded ... field of diagnostic imaging for PET and SPECT. "ImaginAb ... BZL as we believe that huJ591 will form the ... and management of prostate cancer. BZL,s technology has extensive ...
... Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: ... treatment phase of its open-label Phase 2a clinical trial ... with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver ... U.S. population. At the completion of the initial six-month ...
Cached Biology Technology:Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 2Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 3ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA) 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 5Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 6
(Date:9/19/2014)... Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ("Nxt-ID" or ... market, updates the "Wocket in Your Pocket" celebrity ad campaign, featuring ... weight classes, Vinny Pazienza (PAZ). , ... Thrones actor Ciaran Hinds and Sons of ... Sagal have been cast in Bleed for This . ...
(Date:9/18/2014)... State University researchers have developed a unique method to ... cleanup in rural areas. , The first microbe-powered, ... and quick way to clean up waste from large ... pollution. , Professor Haluk Beyenal and graduate student ... Architecture discuss the system in the online edition of ...
(Date:9/18/2014)... located deep in the primitive brainstem has revealed how ... Harvard School of Medicine and the University at Buffalo ... the second "sleep node" identified in the mammalian brain ... to produce deep sleep. , Published online in August ... fully half of all of the brain,s sleep-promoting activity ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Researchers develop unique waste cleanup for rural areas 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... According to a new report on regional marine research ... research about fisheries, ocean health, coastal hazards and climate ... protect the region,s annual $32-billion ocean-related economy, according to ... Grant programs. The report, West Coast Regional Marine ...
... German . , Several thousand test fields are ... They permit the rapid analysis of substances, e.g. for diagnosing ... use for DNA testing. When it comes to proteins, such ... have a defined three-dimensional structure by which they can interact ...
... Davis, CA Researchers from the University of California, Davis ... of the fragile X mental retardation 1 (FMR1) protein (FMRP), ... report by Iwahashi et al, "A quantitative ELISA assay for ... July 2009 issue of the Journal of Molecular Diagnostics ...
Cached Biology News:West Coast needs more research on fisheries, marine science, climate change 2Proteins in gel 2Measuring intellectual disability 2